Product Description: Ciproxifan (FUB 359) is a potent, selective, orally bioavailable and competitive antagonist of histamine H3-receptor, with an IC50 of 9.2 nM. Ciproxifan displays low apparent affinity at other receptor subtypes. Ciproxifan can be used for the research of aging disorders and Alzheimer's disease[1][3].
Applications: Metabolism-protein/nucleotide metabolism
Formula: C16H18N2O2
References: [1]Motawaj M, Arrang JM.
Ciproxifan, a histamine H?-receptor antagonist?/?inverse agonist, modulates methamphetamine-induced sensitization in mice.
Eur J Neurosci. 2011 Apr;33(7):1197-204. doi: 10.1111/j.1460-9568.2011.07618.x./[2]Bardgett ME, et al.
Ciproxifan, an H3 receptor antagonist, alleviates hyperactivity and cognitive deficits in the APP Tg2576 mouse model of Alzheimer's disease.
Neurobiol Learn Mem. 2011 Jan;95(1):64-72./[3]Bardgett ME, et al.
The H3 antagonist, ciproxifan, alleviates the memory impairment but enhances the motor effects of MK-801 (dizocilpine) in rats.
Neuropharmacology. 2010 Nov;59(6):492-502./[4]Day M, et al.
Differential effects of ciproxifan and nicotine on impulsivity and attention measures in the 5-choice serial reaction time test.
Biochem Pharmacol. 2007 Apr 15;73(8):1123-34./[5]Pillot C, et al.
Ciproxifan, a histamine H3-receptor antagonist/inverse agonist, modulates the effects of methamphetamine on neuropeptide mRNA expression in rat striatum.
Eur J Neurosci. 2003 Jan;17(2):307-14./[6]Ligneau X, et, al. Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist. J Pharmacol Exp Ther. 1998 Nov;287(2):658-66.
CAS Number: 184025-18-1
Molecular Weight: 270.33
Compound Purity: 99.26
Research Area: Neurological Disease; Endocrinology
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: Histamine Receptor
English
Deutsch
